IPO registrations (S-1, F-1) · Registrants
VACCINEX, INC.
- SEC CIK
- 1205922 · filings on EDGAR ↗
- Former names
- VACCINEX INC (2002–2005)
- Registration
- Form S-1, first filed 2018-07-09, last 2023-09-26; 2 initial registrations, 3 amendments
- Outcome
- Final prospectus filed 2018-08-10; declared effective 2018-08-09
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- DE
- Business address
- 1895 MOUNT HOPE AVE, Rochester, NY 14620
- EIN
- 16-1603202
- Ticker
- VCNX (OTC)
- EDGAR entity type
- operating
- Insiders and CEO pay
- VACCINEX, INC. on the corporate pages
Offering terms
- Proposed price range
- $12.00–$15.00 per share (S-1/A filed 2018-08-08)
- Final price
- $12.00 per share, within the range (424B4 filed 2018-08-10, an initial public offering)
- Shares sold
- 3,333,334
- Gross proceeds
- $40,000,008 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol VCNX
- Lead underwriters
- Oppenheimer
- Syndicate
- BTIG (1,166,667); Ladenburg Thalmann (666,667)
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Business registration: VACCINEX, INC. Fuzzy (name and state)
- Form 5500 plan sponsor: VACCINEX INC EXACT (EIN (EXACT))
- Form D issuer: VACCINEX, INC. EXACT (CIK (EXACT))
- SEC filer: VACCINEX, INC. EXACT (CIK (EXACT))
Filings 39
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2018-07-09 | S-1 | S-1 (registration) | VACCINEX, INC. | 0001193125-18-214817 ↗ |
| 2018-07-23 | S-1/A | S-1/A (amendment) | VACCINEX, INC. | 0001193125-18-223205 ↗ |
| 2018-08-08 | S-1/A | S-1/A (amendment) | VACCINEX, INC. | 0001193125-18-241451 ↗ |
| 2018-08-09 | EFFECT | EFFECT (declared effective) | VACCINEX, INC. | 9999999995-18-002057 ↗ |
| 2018-08-10 | 424B4 | 424B4 (final prospectus) | VACCINEX, INC. | 0001193125-18-246127 ↗ |
| 2019-10-08 | EFFECT | EFFECT (declared effective) | VACCINEX, INC. | 9999999995-19-002272 ↗ |
| 2020-03-11 | EFFECT | EFFECT (declared effective) | VACCINEX, INC. | 9999999995-20-000551 ↗ |
| 2020-03-11 | EFFECT | EFFECT (declared effective) | VACCINEX, INC. | 9999999995-20-000552 ↗ |
| 2020-08-25 | EFFECT | EFFECT (declared effective) | VACCINEX, INC. | 9999999995-20-002254 ↗ |
| 2020-08-25 | EFFECT | EFFECT (declared effective) | VACCINEX, INC. | 9999999995-20-002255 ↗ |
| 2022-04-27 | EFFECT | EFFECT (declared effective) | VACCINEX, INC. | 9999999995-22-001124 ↗ |
| 2023-01-31 | EFFECT | EFFECT (declared effective) | VACCINEX, INC. | 9999999995-23-000245 ↗ |
| 2023-04-12 | EFFECT | EFFECT (declared effective) | VACCINEX, INC. | 9999999995-23-000913 ↗ |
| 2023-07-10 | EFFECT | EFFECT (declared effective) | VACCINEX, INC. | 9999999995-23-002038 ↗ |
| 2023-09-14 | S-1 | S-1 (registration) | VACCINEX, INC. | 0001193125-23-235408 ↗ |
| 2023-09-26 | S-1/A | S-1/A (amendment) | VACCINEX, INC. | 0001193125-23-241928 ↗ |
| 2023-09-28 | S-1MEF | S-1MEF (added securities) | VACCINEX, INC. | 0001193125-23-246045 ↗ |
| 2023-09-28 | EFFECT | EFFECT (declared effective) | VACCINEX, INC. | 9999999995-23-002823 ↗ |
| 2023-10-02 | 424B4 | 424B4 (final prospectus) | VACCINEX, INC. | 0001193125-23-248527 ↗ |
| 2024-01-19 | EFFECT | EFFECT (declared effective) | VACCINEX, INC. | 9999999995-24-000161 ↗ |
| 2024-04-16 | EFFECT | EFFECT (declared effective) | VACCINEX, INC. | 9999999995-24-000987 ↗ |
| 2024-05-08 | EFFECT | EFFECT (declared effective) | VACCINEX, INC. | 9999999995-24-001488 ↗ |
| 2024-07-05 | EFFECT | EFFECT (declared effective) | VACCINEX, INC. | 9999999995-24-002085 ↗ |
| 2024-10-24 | EFFECT | EFFECT (declared effective) | VACCINEX, INC. | 9999999995-24-003276 ↗ |
| 2025-03-25 | EFFECT | EFFECT (declared effective) | VACCINEX, INC. | 9999999995-25-000746 ↗ |
| 2025-03-25 | EFFECT | EFFECT (declared effective) | VACCINEX, INC. | 9999999995-25-000747 ↗ |
| 2025-03-25 | EFFECT | EFFECT (declared effective) | VACCINEX, INC. | 9999999995-25-000749 ↗ |
| 2025-03-25 | EFFECT | EFFECT (declared effective) | VACCINEX, INC. | 9999999995-25-000750 ↗ |
| 2025-03-25 | EFFECT | EFFECT (declared effective) | VACCINEX, INC. | 9999999995-25-000752 ↗ |
| 2025-03-25 | EFFECT | EFFECT (declared effective) | VACCINEX, INC. | 9999999995-25-000754 ↗ |
| 2025-03-25 | EFFECT | EFFECT (declared effective) | VACCINEX, INC. | 9999999995-25-000755 ↗ |
| 2025-03-25 | EFFECT | EFFECT (declared effective) | VACCINEX, INC. | 9999999995-25-000756 ↗ |
| 2025-03-25 | EFFECT | EFFECT (declared effective) | VACCINEX, INC. | 9999999995-25-000757 ↗ |
| 2025-03-25 | EFFECT | EFFECT (declared effective) | VACCINEX, INC. | 9999999995-25-000758 ↗ |
| 2025-03-25 | EFFECT | EFFECT (declared effective) | VACCINEX, INC. | 9999999995-25-000761 ↗ |
| 2025-03-25 | EFFECT | EFFECT (declared effective) | VACCINEX, INC. | 9999999995-25-000762 ↗ |
| 2025-03-25 | EFFECT | EFFECT (declared effective) | VACCINEX, INC. | 9999999995-25-000763 ↗ |
| 2025-03-25 | EFFECT | EFFECT (declared effective) | VACCINEX, INC. | 9999999995-25-000765 ↗ |
| 2025-03-25 | EFFECT | EFFECT (declared effective) | VACCINEX, INC. | 9999999995-25-000768 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2018-08-08 | S-1/A | registration statement | $12.00–$15.00 | $9.50 | 3,333,000 | $31,663,500 | Nasdaq VCNX | 3 | primary document; range, price line, shares headline, proceeds computed, cover names 3 | document ↗ |
| 2018-08-10 | 424B4 | final prospectus | $12.00 | 3,333,334 | $40,000,008 | Nasdaq VCNX | 3 | primary document; price sentence, shares headline, proceeds table, underwriting table 2, cover names 3 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Antibody Investments LLC | TenPercentOwner | 2 | 2018 | ||
| Berlin Alejandro M. | Director | 2 | 2018–2019 | ||
| FCMI Parent Co. | TenPercentOwner | 28 | 2018–2024 | ||
| Frieberg Jacob B. | Director | 33 | 2018–2024 | ||
| FRIEDBERG ALBERT | Director,TenPercentOwner | 30 | 2018–2024 | ||
| Goater Jeff | Director | 4 | 2018–2021 | ||
| Leonard John E. | Officer | SVP, Development | 9 | 2018–2023 | |
| MANIAN BALA S | Director | 7 | 2018–2024 | ||
| Royer Scott E. | Officer | Chief Financial Officer | 10 | 2018–2023 | |
| Shumacher Michael | TenPercentOwner | 2 | 2018 | ||
| Smith Ernest S. | Officer | SVP, Research & CSO | 8 | 2018–2024 | |
| Vaccinex (Rochester), L.L.C. | TenPercentOwner | 10 | 2018–2024 | ||
| Van Strydonck, Gerald E. | Director | 16 | 2018–2024 | ||
| Watkins Raymond E. | Officer | SVP & Chief Operating Officer | 3 | 2018–2020 | |
| Yanni Barbara | Director | 7 | 2018–2024 | ||
| Zauderer Maurice | Director,Officer; Director,Officer,TenPercentOwner | President and CEO | 21 | 2018–2024 | |
| Crane Alan L | Director | 2 | 2019 | ||
| VACCINEX, INC. | Director | 4 | 2019 | ||
| Stecyk Chrystyna Bedrij | Director | 6 | 2020–2024 | ||
| Scala Robert | Officer | Chief Commercial Officer | 2 | 2020 | |
| Evans Elizabeth E. | Officer | Chief Operating Officer | 5 | 2021–2024 | |
| Sanchez Jill | Officer | Chief Financial Officer; Interim CFO | 3 | 2024 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2024-09-27 | VACCINEX, INC. | Pharmaceuticals | $9,224,732 | $200,155 | 8 | 1 |
| 2024-04-12 | VACCINEX, INC. | Pharmaceuticals | $1,474,520 | $0 | 4 | 1 |
| 2024-04-12 | VACCINEX, INC. | Pharmaceuticals | $3,499,995 | $1,750,000 | 1 | 1 |
| 2024-04-12 | VACCINEX, INC. | Pharmaceuticals | $2,462,090 | $1,240,737 | 3 | 1 |
| 2020-09-16 | VACCINEX, INC. | Pharmaceuticals | $2,000,000 | $2,000,000 | 1 | 1 |
| 2020-08-11 | VACCINEX, INC. | Pharmaceuticals | $8,000,000 | $8,000,000 | 1 | 1 |
| 2020-07-15 | VACCINEX, INC. | Pharmaceuticals | $4,000,000 | $4,000,000 | 1 | 1 |
| 2020-02-03 | VACCINEX, INC. | Pharmaceuticals | $7,474,986 | $7,474,986 | 5 | 1 |
| 2019-08-14 | VACCINEX, INC. | Pharmaceuticals | $13,799,915 | $13,799,915 | 5 | 1 |
| 2017-07-07 | VACCINEX, INC. | Biotechnology | $18,200,000 | $6,000,000 | 1 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Business registration | VACCINEX, INC. | NY | State business registries | name and state |
| Form D issuer | VACCINEX, INC. | NY | Form D private offerings | CIK (EXACT) |
| Patent assignee | Vaccinex, Inc. | NY | Patents (USPTO) | name and state |
| SEC filer | VACCINEX, INC. | SEC filers (EDGAR) | CIK (EXACT) | |
| Trademark owner | Vaccinex, Inc. | NY | Trademarks (USPTO) | name and state |
| Form 5500 plan sponsor | VACCINEX INC | EIN (EXACT) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Pharmaceutical Preparations, NY first:
- TG THERAPEUTICS, INC. NY
- SIGA TECHNOLOGIES INC NY
- SEELOS THERAPEUTICS, INC. NY
- Protagenic Therapeutics, Inc.\new NY
- XTL BIOPHARMACEUTICALS LTD NY
- PENWEST PHARMACEUTICALS CO NY
- CHEMBIO DIAGNOSTICS, INC. NY
- EYETECH PHARMACEUTICALS INC NY
- INNOVATIVE DRUG DELIVERY SYSTEMS INC NY
- EON LABS INC NY
In other datasets, the same topic (Health) in NY:
- Nonprofit: AABR FOUNDATION INC (Nonprofits (IRS Form 990))
Interests: Pharmaceutical Preparations · Health